Sanofi Partners with Novavax to Co-commercialize COVID-19 Vaccine and Develop Flu-COVID-19 Combination Vaccines
Shots:
- Agreement grants co-exclusive rights to Sanofi to co-commercialize Novavax’s adj. COVID-19 vaccine globally (excl. Advance Purchase Agreements existing countries, India, Japan, S. Korea); exclusive license to combine COVID-19 vaccine with flu vaccines & non-exclusive license to develop vaccines using Matrix-M adjuvant technology
- Novavax to obtain $500M up front, ~$700M R&D, regulatory & launch milestones and tiered double-digit royalties on sales. Additional $200M launch & sales milestones plus mid-single digit royalties for each additional vaccine developed using technology. Sanofi will also take <5% equity investment
- Sanofi to book Novavax's COVID-19 vaccine’s sales starting in 2025, will support R&D, regulatory & commercial cost and solely develop & market the flu-COVID-19 combination vaccine. Outside collaboration, both companies are solely responsible to develop and market their products
Ref: Sanofi | Image: Sanofi
Related News:- Sanofi’s Rilzabrutinib Meets Primary Endpoint of the LUNA-3 (P-III) Study for the Treatment of Immune Thrombocytopenia (ITP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
